Century Therapeutics (NASDAQ:IPSC) Announces Earnings Results

Century Therapeutics (NASDAQ:IPSC) issued its quarterly earnings data on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.01, FiscalAI reports.

Century Therapeutics Trading Up 0.9%

Shares of NASDAQ IPSC traded up $0.01 during midday trading on Friday, reaching $1.64. The company’s stock had a trading volume of 215,497 shares, compared to its average volume of 1,222,422. The stock has a 50 day simple moving average of $1.65 and a 200-day simple moving average of $2.07. The stock has a market capitalization of $297.68 million, a price-to-earnings ratio of -1.76 and a beta of 1.78. Century Therapeutics has a fifty-two week low of $0.43 and a fifty-two week high of $3.04.

Wall Street Analyst Weigh In

A number of research firms have issued reports on IPSC. Weiss Ratings reiterated a “sell (d-)” rating on shares of Century Therapeutics in a report on Tuesday, September 29th. Wall Street Zen lowered Century Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Century Therapeutics has a consensus rating of “Hold” and a consensus target price of $4.75.

Century Therapeutics Company Profile

Century Therapeutics is a biotechnology company developing cell-based therapies for cancer and other serious diseases. Its research focuses on allogeneic treatments, which are designed to be produced from donor cells rather than made separately for each patient. The company uses induced pluripotent stem cell technology to create immune cells, including natural killer cells and T cells, that can be engineered to recognize and attack disease. Its work includes developing cell therapies with genetic modifications intended to improve their activity and persistence.